MB-32 * FEASIBILITY OF VORINOSTAT COMBINED WITH ISOTRETINOIN AND CHEMOTHERAPY FOR YOUNG CHILDREN WITH NEWLY DIAGNOSED EMBRYONAL BRAIN TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY
Sarah Leary(Seattle Children's Hospital), Maryam Fouladi(Nationwide Children's Hospital), Mehmet Koçak(St. Jude Children's Research Hospital), Lindsay Kilburn(Children's National), T. MacDonald(Children's Healthcare of Atlanta), James M. Olson(Fred Hutch Cancer Center), J. Geyer(Cincinnati Children's Hospital Medical Center), David W. Ellison(St. Jude Children's Research Hospital), L. Kun(Radiation Oncology Associates), James M. Boyett(University of Illinois Chicago), Tina Young Poussaint(Seattle Children's Hospital), Arzu Onar(Northwestern University), Ralph P. Ermoian(University of Washington)
Cited by 5
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
|Journal of Clinical Oncology|2010|657
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488